MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients

  • End date
    Jun 24, 2023
  • participants needed
  • sponsor
    Zai Lab (Shanghai) Co., Ltd.
Updated on 24 January 2021


This study consists of two parts: Phase I is a dose escalation study to determine the Recommended Phase II Dose (RP2D) of MGD013 monotherapy and that of MGD013 when in combination with Brivanib Alaninate (ZL-2301) in subjects with advanced liver cancer (including hepatocellular carcinoma and intrahepatic cholangiocarcinoma). Phase II is a dose expansion study and consists of two parts: Part 1 is to assess the safety and efficacy of MGD013 monotherapy and MGD013 in combination with ZL-2301 in subjects with advanced hepatocellular carcinoma (HCC); in Part 2, a therapeutic method (MGD013 monotherapy or MGD013 in combination with ZL-2301, determined by the sponsor according to the obtained data) will be selected for dose expansion study in HCC subjects who have previously failed immune checkpoint inhibitor treatment, to further evaluate the safety and efficacy of the study treatments in the specific group of subjects.

Condition Advanced Hepatocellular Carcinoma
Treatment MGD013 monotherapy, MGD013 in combination with Brivanib Alaninate
Clinical Study IdentifierNCT04212221
SponsorZai Lab (Shanghai) Co., Ltd.
Last Modified on24 January 2021


Yes No Not Sure

Inclusion Criteria

Subjects who voluntarily sign the informed consent form (ICF)
Male or female subjects who are aged 18-75 years old
Subjects with histologic, cytologic or clinical confirmed diagnosis of advanced HCC (Phase I could include intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma), and are not suitable for surgery or loco-regional therapy or have progressed following surgery and/or loco-regional therapy
Subject who has at least one measurable lesion according to RECIST v1.1 criteria
Phase I study: subjects who have previously received at least one line of systemic therapy, including immune checkpoint inhibitors, molecular targeted drugs or systematic chemotherapy, alone or in combination, and failed (progression confirmed by imaging) or were intolerant at the discretion of investigator; PhaseIIAdvanced HCC cohort with subjects who have previously received immune checkpoint inhibitor treatment: subjects who have failed (progression confirmed by imaging) prior one line immune checkpoint inhibitor treatment, including anti-PD-1 antibody/anti-PD-L1 antibody and / or anti-CTLA-4 antibody, and/or molecular targeted therapy or systematic chemotherapy (monotherapy or in combination); Phase II: Advanced HCC cohort with subjects who have not previously received immune checkpoint inhibitor treatment: subjects who have failed (progression confirmed by imaging) or were intolerant to (at the discretion of investigator) previous molecular targeted therapy or systematic chemotherapy, without receiving immune checkpoint inhibitor treatment (including anti-PD-1 antibody, anti-PD-L1 antibody, anti-CTLA-4 antibody, and bispecific antibodies including the above targets)
Previous anti-tumor therapy must be completed no less than 2 weeks prior to the study treatment and all adverse events related to previous treatment must have recovered to CTCAE Grade 1; if subjects who have received prior immune checkpoint inhibitors have immune-related endocrinopathy, it should be controlled with hormone replacement therapy
Phase I: Child-Pugh Class A; Phase II: Child-Pugh Class A or B with a score of 7
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Subjects with life expectancy 12 weeks
Subjects with chronic HBV infection must have HBV-DNA <500 IU/ml, and have received at least 14 days of anti-HBV treatment (e.g. entecavir, tenofovir) prior to the initiation of study treatment and are willing to receive antiviral treatment throughout the study; Subjects with RNA-positive HCV must have received standard antiviral treatment and the elevation of their liver enzymes must not exceed the level of CTCAE Grade 1
Adequate vital organ function as shown below
(1) Blood system function (subjects must have not received blood transfusion
or stimulating growth factors within 14 days prior to screening test)
neutrophil count 1.5109/L, platelet count 75109/L, hemoglobin 90 g/L; (2)
Liver and kidney function (no albumin transfusion within 14 days prior to
screening test): serum total bilirubin 2.5ULN, serum albumin 29 g/L, ALT and
AST 5ULN; serum creatinine <1.5ULN or eGFR (Cockcroft-Gault formula) 60
ml/min; (3) Coagulation function: international normalized ratio (INR)2.3 or
prothrombin time (PT) of 6 seconds above control; (4) Left ventricular
ejection fraction (LVEF) 50% by two-dimensional echocardiography
\. Female subjects (except for females who have underwent surgical
sterilization and those have been menopausal for more than one year) who are
of childbearing potential are required to adopt a medically proven method for
contraception (e.g. intrauterine contraception device, contraceptive pill or
condom) throughout the study and up to 120 days after the last dose of
investigational products; females who are of childbearing age and who do not
underwent surgical sterilization must have negative serum or urine HCG tests
within 7 days prior to enrollment; female subjects must not be breastfeeding
male subjects whose partners are of childbearing potential should use
effective contraceptive methods throughout the study and up to 120 days after
the last dose of investigational product
\. Subjects who are willing to provide oncological tissues (if applicable)
for biomarker test

Exclusion Criteria

Subjects who have known fibrolamellar carcinoma of liver for phase I and subjects who have fibrolamellar carcinoma, mixed HCC- cholangiocarcinoma or cholangiocarcinoma for phase II
Subjects with brain metastasis or leptomeningeal metastasis confirmed by brain MRI during screening period
Subjects with a diagnosis of other malignant tumors within 5 years prior to first administration, except for skin basal cell carcinoma, skin squamous cell carcinoma and/or in situ cancer following radical resection
Subjects who had liver or other sites loco-regional treatment (including transcatheter arterial chemoembolization (TACE), transcatheter arterial embolization (TAE), hepatic artery infusion (HAI), local radiotherapy, radioembolization, radiofrequency ablation, cryoablation or percutaneous ethanol injection) , or who had major surgery of liver or other sites within 4 weeks prior to first administration, or had minor surgical procedures (e.g. simple excision, tooth extraction) within one week prior to first administration, or had received palliative radiotherapy for bone metastasis within 2 weeks and radiotherapy-related toxicity CTCAE Grade 2
Subjects who have moderate or severe ascites (detected by B-ultrasound or CT), or require therapeutic abdominal paracentesis or drainage
Subjects with a history of hepatic encephalopathy
Subjects with a history of unhealed wounds or ulcers or bone fractures within 3 months prior to study enrollment
Subjects who plan to have or had allogenic organ or bone marrow transplantation
Subjects who are at increased risk of bleeding or have history of thrombosis
(1) Clinically significant bleeding within 3 months prior to screening or
clear bleeding tendency; (2) Gastrointestinal hemorrhage within 6 months prior
to screening or clear tendency of gastrointestinal hemorrhage; (3)
Arterial/venous thromboembolic events within 6 months prior to screening, such
as cerebrovascular accident (including transient ischemic attack), pulmonary
embolism, etc.; (4) Require anticoagulation therapy with an agent such as
warfarin or heparin; (5) Require chronic anti-platelet therapy (such as
aspirin100 mg/day, clopidogrel, etc.); 10. Subjects who have clinically
significant cardiovascular
NYHA (New York Heart Association)stage 3 and 4 congestive heart failure
Unstable angina pectoris or newly diagnosed angina pectoris or myocardial infarction within 12 months prior to screening
Arrhythmias requiring medications other than -blockers
Valvular heart disease of CTCAE grade 2
Hypertension inadequately controlled by drugs (systolic pressure >150 mmHg or diastolic pressure >90 mmHg); 11. Subjects who have history of symptomatic pulmonary fibrosis, or have interstitial pneumonitis, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis, severe impairment of pulmonary function, or other suspicious pulmonary diseases that may interfere with drug-related pulmonary toxicity detection and treatment; 12. Subjects who have suffered active bacterial or fungal infections requiring systemic treatment within 7 days prior to screening; or active tuberculosis
Subjects with active co-infection of Hepatitis B and C, confirmed by positive HBV surface antigen or HBV DNA and HCV RNA 14. Subjects who have any active, known or suspected autoimmune disease; 15. Subjects with a condition requiring systematic treatment with corticosteroids (>10 mg/day prednisone or equivalent) or other immunosuppressive drugs within 14 days before administration of the investigational drug. In the absence of active autoimmune diseases, inhalation or topical use of steroids (>10 mg/day prednisone or equivalent) is allowed; 16. Other laboratory
(1) Hyponatremia, hypokalemia or hypophosphatemia that have occurred before
the first administration, and failed to restore to normal level after
electrolyte supplementation therapy; (2) Confirmed diagnosis of thyroid
dysfunction, which cannot be maintained within normal range following thyroid
hormone replacement therapy; (3) Positive Human immunodeficiency virus (HIV)
test; 17. QTc interval >480 ms on two consecutive ECGs; 18. Female subjects
during pregnancy or lactation; female subjects of childbearing potential or
male subjects who are not willing to use contraception or contraceptive
measures during the study; 19. Subjects who have previously received two lines
and above tumor immune checkpiont inhibitor treatment, mainly including anti-
PD-1, anti-PD-L1 and anti-CTLA-4 antibodies, etc, or bispecific antibodies
including the above targets, or received anti-LAG-3 antibody; whether subjects
who have previously received other tumor immunotherapy can be enrolled should
be determined by the sponsor; 20. Known or suspected history of severe allergy
to investigational drugs; 21. Subjects who have received live attenuated
vaccines or any investigational drugs that have not been marketed in China
within 4 weeks prior to first administration; 22. If subjects who have
previously used immune checkpoint inhibitors (such as anti-PD-1, anti-PD-L1
anti-CTLA-4 antibodies) have the following drug-related adverse events, they
will be not suitable for inclusion regardless of recovered or not
Grade 3 eye-related adverse events
Grade 4 abnormal liver function
Grade 3 neurotoxicity
Grade 3 colitis
Grade 3 renal toxicity
Grade 3 pneumonitis 23. Subjects who are not suitable for inclusion as judged by the investigators
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note